FDA approved the first new kind of pain medication in 27 years. Here’s how it works
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.
Hosted on MSN54m
New type of non-opioid pain medication approved by FDA
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
FDA approves suzetrigine, the first new painkiller since 1998
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the agency since 1998.
FDA Approves New Non-Opioid Painkiller, Journavx: 'No Addiction Potential'
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
Roche Gets FDA Approval for Breast Cancer Test
The Swiss pharmaceutical company said the FDA backed a label expansion for the Pathway HER2 (4B5) test to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who could be ...
FDA approves first new non-opioid pain pill in decades
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...
FDA approves new medication as alternative to opioids for pain treatment
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.
Monthly Prescribing Reference1h
Journavx, a Nonopioid Oral Pain Medication, Gets FDA Approval
The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
No Opioids, No Addiction: FDA Approves First New Type of Painkiller in Decades
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data
Elicio Therapeutics aims for breakthrough treatment with ELI-002 in pancreatic cancer. Find out why ELTX stock may benefit ...